Long‐Term Efficacy and Safety of Ravulizumab in Adults With Anti‐Acetylcholine Receptor Antibody‐Positive Generalized Myasthenia Gravis: Final Results From the Phase 3 CHAMPION MG Open‐Label Extension
European Journal of Neurology · 2025-04 · 32 (4)
DOI: 10.1111/ene.70158 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Neurology, online erschienen am 16.04.2025. Verfasst von Tuan H Vu und 10 weiteren Autor:innen. Beteiligte Einrichtung: University of South Florida Morsani College of Medicine, Tampa, Florida, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Autoantibodies, Myasthenia Gravis, Receptors, Cholinergic. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Alexion, AstraZeneca Rare Disease, Alexion Pharmaceuticals.
Abstract (Originalsprache)
Background
Ravulizumab, an anti‐complement C5 monoclonal antibody, was efficacious with acceptable safety in the randomized controlled period (RCP) and interim open‐label extension (OLE) periods of the CHAMPION MG phase 3 trial in adults with anti‐acetylcholine receptor antibody‐positive (AChR‐Ab+) generalized myasthenia gravis (gMG). Here, we report final results from the OLE.
Methods
Patients who completed the 26‐week RCP could enter the OLE and receive ravulizumab for up to 4 years. Efficacy and safety were assessed throughout the OLE.
Results
Among all ravulizumab‐treated patients ( n = 169; median [range] ravulizumab treatment, 759.0 [14.0, 1265.0] days), 161 entered the OLE (ravulizumab‐ravulizumab: n = 78; placebo‐ravulizumab: n = 83). Sustained improvements were observed in Myasthenia Gravis Activities of Daily Living (MG‐ADL) total scores (ravulizumab‐ravulizumab, least squares mean [95% CI] change from RCP baseline at week 164: −4.0 [−5.3, −2.8]; p < 0.0001; placebo‐ravulizumab, change from OLE baseline after 138 weeks of treatment: −2.1 [−3.3, −0.9]; p = 0.0005). One hundred and forty‐one out of 160 (88.1%) patients achieved a ≥ 2‐point improvement in MG‐ADL total score, and 59/141 (41.8%) achieved a score of 0 or 1; once achieved, 32/59 (54.2%) sustained this status for > 50% of their remaining time in the study. Similar improvements were observed in Quantitative Myasthenia Gravis and Myasthenia Gravis Quality of Life‐15 revised scores, and Neurological Quality of Life Fatigue subscale scores. Clinical deterioration event rates were reduced in the OLE versus placebo in the RCP. Corticosteroid usage was reduced in the OLE. Ravulizumab was well tolerated; no meningococcal infections were reported.
Conclusion
Ravulizumab demonstrated clinically meaningful and durable efficacy and safety in adults with AChR‐Ab+ gMG.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of South Florida Morsani College of Medicine, Tampa, Florida, USA.
- Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
- Hôpital Raymond Poincaré, Garches, University Paris Saclay-UVSQ, Garches, France.
- Nagoya University Graduate School of Medicine, Nagoya, Japan.
- Charité Universitätsmedizin Berlin, Berlin, Germany.
- London Health Sciences Centre, London, Ontario, Canada.
ORCID-Profile: Masahisa Katsuno, Andreas Meisel, Vera Bril, James F Howard
Förderung
- Alexion, AstraZeneca Rare Disease
- Alexion Pharmaceuticals
Zitieren
APA
Vu, T. H., Mantegazza, R., Annane, D., Katsuno, M., Meisel, A., Nicolle, M. W., Bril, V., Aguzzi, R., Frick, G., Howard, J. F., & CHAMPION MG Study Group (2025). Long‐Term Efficacy and Safety of Ravulizumab in Adults With Anti‐Acetylcholine Receptor Antibody‐Positive Generalized Myasthenia Gravis: Final Results From the Phase 3 CHAMPION MG Open‐Label Extension. European Journal of Neurology, 32(4). https://doi.org/10.1111/ene.70158
Vancouver
Vu TH, Mantegazza R, Annane D, Katsuno M, Meisel A, Nicolle MW, et al. Long‐Term Efficacy and Safety of Ravulizumab in Adults With Anti‐Acetylcholine Receptor Antibody‐Positive Generalized Myasthenia Gravis: Final Results From the Phase 3 CHAMPION MG Open‐Label Extension. European Journal of Neurology. 2025;32(4). doi:10.1111/ene.70158
BibTeX
@article{Vu2025,
author = {Vu, Tuan H and Mantegazza, Renato and Annane, Djillali and Katsuno, Masahisa and Meisel, Andreas and Nicolle, Michael W and Bril, Vera and Aguzzi, Rasha and Frick, Glen and Howard, James F and CHAMPION MG Study Group, CHAMPION MG Study Group},
title = {Long‐Term Efficacy and Safety of Ravulizumab in Adults With Anti‐Acetylcholine Receptor Antibody‐Positive Generalized Myasthenia Gravis: Final Results From the Phase 3 CHAMPION MG Open‐Label Extension},
journal = {European Journal of Neurology},
year = {2025},
volume = {32},
number = {4},
doi = {10.1111/ene.70158}
}
EUVIMED